Tech Times on MSN
Nasal mRNA drug cuts common cold virus load 40-fold in asthma patients, validating COVID-vaccine technology as a respiratory antiviral
Intranasal mRNA therapy for asthma reduced rhinovirus viral load 40-fold versus placebo in a Phase 2a trial, Ethris announced November 5. The drug, ETH47, also cut lower respiratory symptoms 58% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results